Liver function may be negatively affected by radiation for treatment of hepatic malignancy. Pretreatment blood cytokine levels are biomarkers for prediction of toxicity and survival after external-beam radiation therapy. We hypothesized that cytokines may also predict outcomes after radioembolization, enabling a biomarker-driven personalized approach to treatment. Methods: Pretherapy blood samples from patients enrolled on a prospective protocol evaluating 90Y radioembolization for management of intrahepatic malignancy were analyzed for 2 cytokines selected on the basis of prior studies in stereotactic body radiotherapy, soluble tumor necrosis factor receptor 1 (sTNFR1) and hepatocyte growth factor (HGF), via enzyme-linked immunosorbent assay, and key dosimetric parameters were derived from posttreatment 90Y PET/CT imaging. Toxicity was defined as a change in albumin-bilirubin score from baseline to follow-up (3-6 mo after treatment). Associations of cytokine levels, dose metrics, and baseline liver function with toxicity and overall survival were assessed. Results: Data from 43 patients treated with 90Y radioembolization for primary (48.8% [21/43]) or secondary (51.2% [22/43]) malignancy were assessed. Examined dose metrics and baseline liver function were not associated with liver toxicity; however, levels of sTNFR1 (P = 0.045) and HGF (P = 0.005) were associated with liver toxicity in univariate models. Cytokines were the only predictors of toxicity in multivariable models including dose metrics and prior liver-directed therapy. sTNFR1 (hazard ratio, 12.3; 95% CI, 3.5-42.5, P < 0.001) and HGF (hazard ratio, 7.5; 95% CI, 2.4-23.1, P < 0.001) predicted overall survival, and findings were similar when models were controlled for absorbed dose and presence of metastatic disease. Conclusion: Pretreatment cytokine levels predict liver toxicity and overall survival. These pathways can be targeted with available drugs, an advantage over previously studied dose metrics and liver function tests. Interventions directed at the TNFα-axis should be considered in future studies for prevention of liver toxicity, and HGF should be explored further to determine whether its elevation drives toxicity or indicates ongoing liver regeneration after prior injury.
Liver function may be negatively affected by radiation for treatment of hepatic malignancy. Pretreatment blood cytokine levels are biomarkers for prediction of toxicity and survival after external-beam radiation therapy. We hypothesized that cytokines may also predict outcomes after radioembolization, enabling a biomarker-driven personalized approach to treatment. Methods: Pretherapy blood samples from patients enrolled on a prospective protocol evaluating 90Y radioembolization for management of intrahepatic malignancy were analyzed for 2 cytokines selected on the basis of prior studies in stereotactic body radiotherapy, soluble tumor necrosis factor receptor 1 (sTNFR1) and hepatocyte growth factor (HGF), via enzyme-linked immunosorbent assay, and key dosimetric parameters were derived from posttreatment 90Y PET/CT imaging. Toxicity was defined as a change in albumin-bilirubin score from baseline to follow-up (3-6 mo after treatment). Associations of cytokine levels, dose metrics, and baseline liver function with toxicity and overall survival were assessed. Results: Data from 43 patients treated with 90Y radioembolization for primary (48.8% [21/43]) or secondary (51.2% [22/43]) malignancy were assessed. Examined dose metrics and baseline liver function were not associated with liver toxicity; however, levels of sTNFR1 (P = 0.045) and HGF (P = 0.005) were associated with liver toxicity in univariate models. Cytokines were the only predictors of toxicity in multivariable models including dose metrics and prior liver-directed therapy. sTNFR1 (hazard ratio, 12.3; 95% CI, 3.5-42.5, P < 0.001) and HGF (hazard ratio, 7.5; 95% CI, 2.4-23.1, P < 0.001) predicted overall survival, and findings were similar when models were controlled for absorbed dose and presence of metastatic disease. Conclusion: Pretreatment cytokine levels predict liver toxicity and overall survival. These pathways can be targeted with available drugs, an advantage over previously studied dose metrics and liver function tests. Interventions directed at the TNFα-axis should be considered in future studies for prevention of liver toxicity, and HGF should be explored further to determine whether its elevation drives toxicity or indicates ongoing liver regeneration after prior injury.
Authors: T S Lawrence; J M Robertson; M S Anscher; R L Jirtle; W D Ensminger; L F Fajardo Journal: Int J Radiat Oncol Biol Phys Date: 1995-03-30 Impact factor: 7.038
Authors: Jin-Yao Teo; John C Allen; David C Ng; Su-Pin Choo; David W M Tai; Jason P E Chang; Foong-Khoon Cheah; Pierce K H Chow; Brian K P Goh Journal: HPB (Oxford) Date: 2015-12-11 Impact factor: 3.647
Authors: Marcin Krawczyk; Simone Zimmermann; Georg Hess; Robert Holz; Marc Dauer; Jochen Raedle; Frank Lammert; Frank Grünhage Journal: PLoS One Date: 2017-03-16 Impact factor: 3.240
Authors: Kyle C Cuneo; Theresa Devasia; Yilun Sun; Matthew J Schipper; David Karnak; Mary A Davis; Dawn Owen; Mary Feng; Issam El Naqa; Latifa Bazzi; Randy Ten Haken; Theodore S Lawrence Journal: Transl Oncol Date: 2019-05-09 Impact factor: 4.243
Authors: Matthew M Cousins; Emily Morris; Christopher Maurino; Theresa P Devasia; David Karnak; Dipankar Ray; Neehar D Parikh; Dawn Owen; Randall K Ten Haken; Matthew J Schipper; Theodore S Lawrence; Kyle C Cuneo Journal: Transl Oncol Date: 2020-12-13 Impact factor: 4.243
Authors: Moyed Miften; Yevgeniy Vinogradskiy; Vitali Moiseenko; Jimm Grimm; Ellen Yorke; Andrew Jackson; Wolfgang A Tomé; Randall K Ten Haken; Nitin Ohri; Alejandra Méndez Romero; Karyn A Goodman; Lawrence B Marks; Brian Kavanagh; Laura A Dawson Journal: Int J Radiat Oncol Biol Phys Date: 2018-01-06 Impact factor: 7.038